PROTONIX I.V. Rx

Indications for PROTONIX I.V.:

Short-term treatment (7–10 days) of GERD associated with a history of erosive esophagitis. Pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).

Adult Dose for PROTONIX I.V.:

≥18yrs: GERD: 40mg once daily for 7–10 days; switch to tabs or oral suspension as soon as possible. Pathological hypersecretory conditions: 80mg every 8–12 hours; usual max 240mg/day or 6 days' treatment.

Children's Dose for PROTONIX I.V.:

<18yrs: not established.

See Also:

PROTONIX for ORAL SUSP

PROTONIX TABLETS

Pharmacological Class:

Proton pump inhibitor.

Warnings/Precautions:

Gastric malignancy. Increased risk of osteoporosis-related fractures of the hip, wrist or spine with long-term and multiple daily dose PPI therapy. Monitor magnesium levels with long-term therapy. Reevaluate periodically. IV: consider zinc supplementation in those prone to zinc deficiency. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:

Concomitant atazanavir or nelfinavir: not recommended. May alter absorption of gastric pH-dependent drugs (eg, ketoconazole, iron, ampicillin). Concomitant digoxin or drugs that may cause hypomagnesemia (eg, diuretics); consider monitoring magnesium levels. Monitor warfarin. May give antacids concomitantly. IV: caution with concomitant other EDTA-containing products. May potentiate methotrexate. May cause false (+) urine THC test.

Adverse Reactions:

Headache, GI upset, dizziness, arthralgia, inj site reactions; also children: upper respiratory infection, fever, rash, abdominal pain; rare: cyanocobalamin deficiency, hypomagnesemia (w. prolonged PPI therapy), possible C. difficile associated diarrhea.

Metabolism:

Hepatic (CYP2C19, 3A4). 98% protein bound.

Elimination:

Renal (primarily), fecal.

Generic Availability:

Tabs, IV (YES); oral soln (NO)

How Supplied:

Tabs—90; Susp—30 packets/box; Vials (40mg)—10, 25